Cargando…
Interleukin‐22 in urinary tract disease – new experimental directions
Interleukin (IL)‐22 is expressed by immune cells in the urinary tract and IL‐22 receptor is expressed in urothelium and renal tubule cells. IL‐22 can be specifically targeted in the urinary tract or conditionally depleted in mice and targeted therapeutically in humans.[Image: see text]
Autores principales: | Ingersoll, Molly A, Starkey, Malcolm R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276185/ https://www.ncbi.nlm.nih.gov/pubmed/32523694 http://dx.doi.org/10.1002/cti2.1143 |
Ejemplares similares
-
The impact of biological sex on diseases of the urinary tract
por: Deltourbe, Léa, et al.
Publicado: (2022) -
The glycobiology of uropathogenic E. coli infection: the sweet and bitter role of sugars in urinary tract immunity
por: Lupo, Federico, et al.
Publicado: (2021) -
Macrophages Subvert Adaptive Immunity to Urinary Tract Infection
por: Mora-Bau, Gabriela, et al.
Publicado: (2015) -
Why Are Children With Bronchiolitis At Risk Of Urinary Tract Infections?
por: Hendaus, Mohamed A
Publicado: (2019) -
Interleukin interrupted: A new strategy for the treatment of pancreatic cancer
por: Leach, Steven D.
Publicado: (2015)